Order Article Reprints

Gupta P, Gupta K, Dockter T, Harlos E, Chow S, Subbiah N, Ruddy KJ, Bazhenova L, Terstriep S, Huang CH, et al. Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. Cancers. 2026; 18(3):373. https://doi.org/10.3390/cancers18030373

Gupta, Pankaj, Kalpna Gupta, Travis Dockter, Elizabeth Harlos, Selina Chow, Niveditha Subbiah, Kathryn J. Ruddy, Lyudmila Bazhenova, Shelby Terstriep, Chao H. Huang, and et al. 2026. "Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study" Cancers 18, no. 3: 373. https://doi.org/10.3390/cancers18030373

Gupta, P., Gupta, K., Dockter, T., Harlos, E., Chow, S., Subbiah, N., Ruddy, K. J., Bazhenova, L., Terstriep, S., Huang, C. H., Kratzke, R. A., Vokes, E. E., & Loprinzi, C. L. (2026). Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study. Cancers, 18(3), 373. https://doi.org/10.3390/cancers18030373